Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Change In Receivables : $-43.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Change In Receivables?

Catalyst Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was $-5.5 Mil. It means Catalyst Pharmaceuticals's Accounts Receivable increased by $5.5 Mil from Sep. 2023 to Dec. 2023 .

Catalyst Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $-43.1 Mil. It means Catalyst Pharmaceuticals's Accounts Receivable increased by $43.1 Mil from Dec. 2022 to Dec. 2023 .

Catalyst Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was $53.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Catalyst Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 44.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Catalyst Pharmaceuticals's liquidation value for the three months ended in Dec. 2023 was $103.4 Mil.

Catalyst Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Catalyst Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Change In Receivables Chart

Catalyst Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-10.54

4.55

-0.63

-3.82

-43.08

Catalyst Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-1.10	-22.96	-9.39	-5.25	-5.47

Catalyst Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.1 Mil.

Catalyst Pharmaceuticals (NAS:CPRX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Catalyst Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	53.514	/	110.568	*	91
=	44.16

2. In Ben Graham's calculation of liquidation value, Catalyst Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Catalyst Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	137.636	-	82.233	+	0.75 * 53.514	+	0.5 * 15.644
=	103.4

Catalyst Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CN2:Germany

Address

355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134

Website

https://www.catalystpharma.com

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Executives

Molly Harper	director	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande	officer: Chief Accounting Officer	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito	officer: Chief Medical Officer	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller	officer: VP Development & Management	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany	director, 10 percent owner, officer: President and Chief Executive	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del	officer: Chief Commercial Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd	officer: Chief Compliance/Legal Officer	355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe	director	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram	officer: Chief Product Devel. Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan	officer: Chief Commercial Officer	C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship	officer: V.P. of Regulatory Operations	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134